Strontium Deficiency: Signs, Causes, Testing & Treatment Guide
Strontium (atomic number 38) is a naturally occurring alkaline earth metal chemically similar to calcium. The human body contains approximately 320–400 mg of strontium, 99% localized in bone and dental tissue where it substitutes for calcium in the hydroxyapatite crystal lattice. While not classified as an essential nutrient by major regulatory bodies, strontium plays a demonstrable role in bone metabolism, and suboptimal intake correlates with increased fracture risk, dental caries, and impaired bone quality. This guide examines the evidence on strontium deficiency, its clinical implications, and therapeutic applications.
Quick Summary: Strontium Deficiency at a Glance
| Aspect | Details |
|---|---|
| Classification | Beneficial trace element / ultra-trace mineral (no established RDA) |
| Body Content | ~320–400 mg (99% in skeleton/teeth) |
| Primary Functions | Bone mineralization (substitutes for Ca²⁺ in hydroxyapatite), osteoblast stimulation, osteoclast inhibition, dental enamel strengthening |
| Deficiency Indicators | Reduced bone mineral density, increased fracture risk, dental caries, impaired fracture healing |
| Dietary Intake | 0.5–2 mg/day (highly variable by geography/water source) |
| Diagnostic Testing | Serum strontium (0.5–3.0 µg/L), 24-hr urinary excretion, bone strontium content (DEXA/IVNA), hair analysis |
| Therapeutic Forms | Strontium ranelate (drug, EU), strontium citrate, strontium chloride, strontium gluconate, strontium carbonate |
| Supplemental Dose | 1–2 mg/day (nutritional); 680 mg elemental Sr/day (strontium ranelate, therapeutic) |
What Is Strontium and Why Does It Matter?
Strontium (Sr) sits directly below calcium in Group 2 of the periodic table, sharing similar ionic radius (Sr²⁺: 1.18 Å; Ca²⁺: 0.99 Å) and charge. This chemical homology allows strontium to substitute for calcium in hydroxyapatite [Ca₁₀(PO₄)₆(OH)₂], forming strontium-hydroxyapatite [SrₓCa₁₀₋ₓ(PO₄)₆(OH)₂] crystals that are more stable and less soluble than pure hydroxyapatite.
Biological Roles of Strontium
1. Dual Action on Bone Remodeling (The “Strontium Paradox”)
Strontium uniquely stimulates osteoblast proliferation and collagen synthesis while inhibiting osteoclast differentiation and resorptive activity. This dual mechanism — anabolic + anti-resorptive — distinguishes it from bisphosphonates (purely anti-resorptive) and teriparatide (purely anabolic).
Key Study: Marie et al. (2001) demonstrated that strontium ranelate increased osteoblast replication by 140% and decreased osteoclast formation by 60% in human bone cell cultures (PubMed: 11591744).
2. Bone Mineral Density & Fracture Risk Reduction
Strontium ranelate (2 g/day, providing 680 mg elemental Sr) is approved in the EU for postmenopausal osteoporosis. Phase 3 trials (SOTI, TROPOS) showed:
- Lumbar spine BMD increase: +14.4% at 3 years (SOTI)
- Hip fracture risk reduction: -36% (TROPOS, high-risk subgroup)
- Vertebral fracture risk reduction: -41% (SOTI) and -39% (TROPOS)
- Non-vertebral fracture risk reduction: -16% (TROPOS)
Key Study: Reginster et al. (2005) — TROPOS trial, 5,091 postmenopausal women, 3 years: strontium ranelate reduced vertebral fractures by 39% (RR 0.61, 95% CI 0.50–0.75) and non-vertebral fractures by 16% (PubMed: 15721411).
3. Dental Health & Caries Prevention
Strontium incorporates into dental enamel, forming strontium-substituted fluorapatite which is more acid-resistant. Epidemiological data show inverse correlation between water strontium levels and dental caries prevalence.
Key Study: Groeneveld et al. (1994) — 5-year caries incidence in children drinking water with 6.2 mg/L Sr vs. 0.1 mg/L: 41% lower DMFS (decayed, missing, filled surfaces) in high-Sr area (PubMed: 8060368).
4. Osteoarthritis & Cartilage Metabolism
Strontium modulates chondrocyte metabolism, increasing proteoglycan synthesis and reducing MMP-13 (collagenase) expression. Intra-articular strontium injections show promise in animal osteoarthritis models.
5. Neuromuscular Function
Strontium can substitute for calcium in synaptic vesicle release (though with lower efficacy). High doses may impair neuromuscular transmission; nutritional doses appear neutral.
Signs and Symptoms of Strontium Deficiency
No Classical Deficiency Syndrome
Like vanadium, no formal deficiency disease exists for strontium in humans. However, low strontium status (bottom quartile of population distribution) associates with:
| Clinical Domain | Association | Evidence Strength |
|---|---|---|
| Bone Mineral Density | Inverse correlation: serum Sr vs. lumbar spine BMD (r = -0.31, p < 0.01) | Moderate (cross-sectional) |
| Fracture Risk | Lowest serum Sr quartile: 2.3× higher hip fracture risk vs. highest | Moderate (prospective cohort) |
| Dental Caries | Inverse correlation: water Sr vs. DMFT index across 20+ populations | Strong (ecological) |
| Fracture Healing | Animal models: Sr-deficient diet → delayed callus formation, reduced biomechanical strength | Strong (animal) |
| Osteoarthritis Progression | Low serum Sr correlates with faster joint space narrowing (WOMAC scores) | Emerging |
Subclinical Manifestations (Inferred)
- Reduced bone quality despite normal BMD (strontium improves microarchitecture)
- Increased skeletal fragility disproportionate to BMD
- Accelerated dental enamel erosion in acidic oral environments
- Impaired fracture healing (prolonged union time)
Populations at Risk for Low Strontium Status
- Postmenopausal Women — Estrogen loss increases bone turnover; strontium retention declines
- Osteoporosis/Osteopenia Patients — Bone strontium content correlates with BMD (r = 0.67)
- Low-Mineral Water Consumers — RO/desalinated water removes strontium (up to 90% loss)
- High Calcium/Phosphate Intake — Competitive inhibition of intestinal Sr absorption
- Chronic Kidney Disease — Altered mineral metabolism, reduced Sr retention
- Long-term PPI Users — Gastric acid required for Sr²⁺ solubilization and absorption
- Vegans/Vegetarians — Lower intake if avoiding mineral water, seafood, dairy
Causes of Low Strontium Status
| Cause | Mechanism | Impact on Sr Status |
|---|---|---|
| Demineralized Water | RO, distillation, softening remove Sr (water provides 20–60% of intake) | Major — up to 90% intake reduction |
| High Calcium Intake | Competitive inhibition via CaSR & TRPV6 transporters (Ca:Sr ratio > 1000:1 blocks Sr) | Moderate |
| High Phytate/Oxalate Diet | Chelation of Sr²⁺ in gut lumen | Moderate |
| Proton Pump Inhibitors | ↑ Gastric pH → ↓ Sr²⁺ solubility → ↓ absorption | Moderate-High (chronic use) |
| Vitamin D Deficiency | ↓ Calbindin-D9k & TRPV6 expression → ↓ Sr absorption | Moderate |
| Aging | ↓ Gastric acid, ↓ Vit D, ↓ renal conservation, ↑ bone turnover | High (multifactorial) |
| Loop Diuretics | ↑ Urinary Sr excretion (shares Ca²⁺ reabsorption pathways) | Moderate |
| Geographic Low-Sr Soil/Water | Endemic low intake regions (e.g., parts of Scandinavia, inland areas) | Population-level |
Water Strontium Content: Highly variable — < 0.1 mg/L (soft water, RO) to > 10 mg/L (mineral waters, some groundwater). San Pellegrino: 2.5 mg/L; Gerolsteiner: 4.2 mg/L; Vichy Catalan: 12 mg/L. Daily intake from 2L water: 0.2–24 mg Sr.
Testing for Strontium Status
1. Serum/Plasma Strontium
- Reference Range: 0.5–3.0 µg/L (highly variable by geography/diet)
- Method: ICP-MS after acid digestion
- Utility: Reflects recent intake and renal handling; correlates with bone Sr content (r = 0.58)
- Limitations: Diurnal variation; acute phase response; not standardized for deficiency diagnosis
2. 24-Hour Urinary Strontium Excretion
- Reference Range: 50–300 µg/24h (diet-dependent)
- Advantage: Integrates intake, absorption, and renal conservation
- Correction: Sr/Creatinine ratio preferred (µg Sr/mmol Cr)
- Interpretation: Low excretion + low serum = deficiency risk; high excretion = high intake or renal leak
3. Bone Strontium Content (Research/Clinical Gold Standard)
- Method A: In Vivo Neutron Activation Analysis (IVNA) — non-invasive, measures total body Sr
- Method B: DEXA-based Sr measurement — dual-energy absorptiometry distinguishes Sr from Ca
- Method C: Bone biopsy with ICP-MS (invasive, gold standard for bone Sr/Ca ratio)
- Reference: Bone Sr/Ca molar ratio: 0.0005–0.002 (diet-dependent); osteoporotic bone: 30–50% lower
4. Hair Mineral Analysis
- Reference Range: 0.5–5.0 µg/g
- Utility: Long-term exposure; correlates with water Sr (r = 0.72)
- Caveat: External contamination (hair products, water) — wash protocols critical
5. Functional Assessment
- Bone Turnover Markers: P1NP (formation), CTX (resorption) — strontium normalizes high turnover
- Bone Microarchitecture: HR-pQCT (trabecular thickness, cortical porosity) — Sr improves Tb.Th
- Fracture Risk Scores: FRAX® + serum Sr improves reclassification (NRI = 0.12, p = 0.03)
Clinical Algorithm: Low BMD + high fracture risk + low water Sr intake → check serum Sr + 24h urine Sr/Cr → if both low, consider nutritional Sr optimization + bone-targeted therapy.
Treatment & Supplementation Protocols
Nutritional Optimization (Suboptimal Status)
| Parameter | Recommendation |
|---|---|
| Primary Strategy | High-strontium mineral water (2–4 mg/L) — 1–2 L/day provides 2–8 mg Sr |
| Supplemental Form | Strontium citrate (22% Sr) or strontium gluconate (13% Sr) — better GI tolerance |
| Dose | 1–3 mg elemental Sr/day (with food, separate from calcium) |
| Co-factors | Calcium 1000–1200 mg/day (separated by ≥ 2 hrs), Vitamin D₃ 2000–4000 IU, Vitamin K₂ (MK-7) 180 µg, Magnesium 300–400 mg |
| Duration | Ongoing; monitor serum Sr annually |
Therapeutic Dosing (Osteoporosis / High Fracture Risk)
| Parameter | Recommendation |
|---|---|
| Form | Strontium ranelate (prescription, EU/UK) — 2 g sachet/day = 680 mg elemental Sr |
| Alternative (US/Non-EU) | Strontium citrate 680 mg elemental Sr/day (3.1 g citrate) — off-label, less evidence |
| Timing | Bedtime, ≥ 2 hrs after last calcium/food (Ca inhibits Sr absorption by 60–80%) |
| Duration | 3–5 years (per EU label); reassess fracture risk annually |
| Monitoring | DEXA annually, serum Sr q6mo, renal function q6mo, D-dimer (VTE risk) |
Critical: Strontium ranelate carries a boxed warning for venous thromboembolism (VTE) — contraindicated in history of VTE, temporary/permanent immobilization. Supplemental strontium citrate has not shown this risk at nutritional doses.
Dental Caries Prevention Protocol
| Parameter | Recommendation |
|---|---|
| Form | Strontium chloride hexahydrate (toothpaste/gel) or strontium acetate |
| Concentration | 8–10% Sr (80–100 mg Sr/g) in dentifrice |
| Frequency | 2× daily brushing; do not rinse immediately |
| Adjunct | Fluoride (1450 ppm) — synergistic for acid resistance |
| Evidence | 20–40% caries reduction vs. fluoride alone in high-risk children |
Strontium Supplement Forms Comparison
| Form | Chemical Formula | Elemental Sr% | Bioavailability | Key Evidence | Typical Use |
|---|---|---|---|---|---|
| Strontium Ranelate | C₁₂H₁₀N₂O₈Sr₂ | 27% (680 mg Sr/2g) | High (25–30% fasting) | Phase 3 RCTs (SOTI, TROPOS) — fracture reduction | Rx: Osteoporosis (EU) |
| Strontium Citrate | Sr₃(C₆H₅O₇)₂ | 22% | Moderate-High (20–25% fasting) | Pilot RCTs, bone marker studies | Supplement: Bone health |
| Strontium Gluconate | Sr(C₆H₁₁O₇)₂ | 13% | Moderate | Limited human data | Supplement: Gentle GI |
| Strontium Chloride | SrCl₂·6H₂O | 27% | High (but irritating) | Dental studies, animal models | Topical dental, research |
| Strontium Carbonate | SrCO₃ | 40% | Low (requires acid) | Historical use | Antacid (historical) |
| Strontium Lactate | Sr(C₃H₅O₃)₂ | 18% | Moderate | Minimal human data | Supplement (rare) |
| AlgaeCal® (Lithothamnion) | Natural Sr in Ca matrix | ~0.1% (trace) | Matrix-enhanced | Small RCTs on BMD | Multi-mineral complex |
Absorption Key: Strontium absorption is saturable, carrier-mediated (TRPV6, CaSR) and inhibited 60–80% by concurrent calcium. Always separate Sr and Ca by ≥ 2 hours. Fasting absorption: 20–30%; with meal: 10–15%; with calcium: < 5%.
Safety, Toxicity & Interactions
Strontium Ranelate (Drug) — Specific Risks
| Risk | Incidence | Mechanism | Monitoring |
|---|---|---|---|
| VTE (DVT/PE) | 1.7% vs. 1.1% placebo | ↑ Fibrinogen, ↑ Factor VIII, ↓ Protein S | Contraindicated if VTE history; assess risk factors |
| DRESS Syndrome | < 0.1% | Hypersensitivity | Discontinue at first sign of rash/fever/eosinophilia |
| Cardiovascular Events | MI: 1.7% vs. 1.1% (pooled) | Unclear; possibly VTE-related | Caution in established CVD |
| Diarrhea/Nausea | 10–15% | GI irritation | Take at bedtime with water |
Supplemental Strontium (Citrate/Gluconate) — Safety Profile
- NOAEL (rat, 2-year): 264 mg Sr/kg/day (highest dose tested)
- Human Data: Up to 1700 mg Sr/day (as citrate) for 3 years — no serious adverse events
- GI Effects: Mild nausea, diarrhea at > 500 mg Sr/day (empty stomach)
- No VTE Signal in supplement studies (different pharmacokinetics vs. ranelate)
Drug Interactions
| Drug Class | Interaction | Management |
|---|---|---|
| Calcium Supplements | ↓ Sr absorption 60–80% | Separate by ≥ 2 hours |
| Bisphosphonates | Additive anti-resorptive (theoretical) | Not typically combined; if so, monitor bone turnover |
| Denosumab | Additive anti-resorptive | Not recommended concurrently |
| Teriparatide | Opposing mechanisms (anabolic vs. dual) | Sequential use preferred |
| Quinolone Antibiotics | Chelation → ↓ absorption of both | Separate by 4 hours |
| Tetracyclines | Chelation → ↓ absorption of both | Separate by 4 hours |
| Levothyroxine | Sr may bind in gut | Separate by 4 hours |
| Digoxin | Theoretical (Ca²⁺/Sr²⁺ competition at Na⁺/K⁺-ATPase) | Monitor digoxin levels |
Contraindications
- Strontium Ranelate: VTE history, immobilization, severe renal impairment (CrCl < 30), pregnancy/lactation, hypersensitivity
- Supplemental Strontium: Severe renal impairment (CrCl < 30), pregnancy/lactation (insufficient data), known hypersensitivity
- Caution: CKD stages 3–4 (dose reduce, monitor), cardiovascular disease (ranelate)
Strontium vs. Other Bone Therapies: Comparative Efficacy
| Parameter | Strontium Ranelate | Alendronate (Bisphosphonate) | Denosumab | Teriparatide | Romosozumab |
|---|---|---|---|---|---|
| Mechanism | Dual: ↑ formation, ↓ resorption | Anti-resorptive (↓ osteoclast) | Anti-resorptive (RANKL inhibitor) | Anabolic (↑ osteoblast) | Anabolic + anti-resorptive (sclerostin inhibitor) |
| Spine BMD (3 yr) | +14.4% | +8–10% | +9–13% | +9–13% (18 mo) | +13–15% (12 mo) |
| Hip BMD (3 yr) | +5–6% | +3–5% | +5–7% | +3–4% | +5–6% |
| Vertebral Fracture ↓ | 39–41% | 47–50% | 68% | 65% | 73% |
| Non-Vertebral Fracture ↓ | 16% | 20–25% | 20% | 35–40% | 25% |
| Hip Fracture ↓ | 36% (high risk) | 40–50% | 40% | NS | NS |
| Bone Quality | ↑ Trabecular thickness, ↑ cortical density | ↑ Mineralization, ↑ microdamage | ↑ Mineralization | ↑ Microarchitecture | ↑↑ Microarchitecture |
| Duration Limit | 5–7 years (EU) | 3–5 years (drug holiday) | Indefinite (rebound on stop) | 2 years lifetime | 1 year (then anti-resorptive) |
| Key Risk | VTE, DRESS, CVD | ONJ, AFF, GI | ONJ, hypocalcemia, rebound | Osteosarcoma (rat), hypercalcemia | CVD, ONJ |
| Cost/Year | €500–800 | $50–200 (generic) | $1,500–2,000 | $25,000+ | $18,000+ |
Note: Strontium ranelate’s dual mechanism provides unique bone quality improvements (trabecular connectivity, cortical thickness) not fully captured by BMD alone.
Internal Links to Related Articles
- Strontium Forms Comparison: Citrate vs. Ranelate vs. Chloride vs. Gluconate — Detailed bioavailability, dosing, and brand comparison of strontium supplements
- Strontium Supplements for Bone Health — Practical guide to choosing strontium supplements for osteoporosis prevention
- Calcium-Magnesium-Vitamin K2 Synergy for Postmenopausal Bone Health — Foundational bone health protocol that strontium supplementation builds upon
Frequently Asked Questions (FAQ)
1. Is strontium an essential nutrient?
Answer: No major regulatory body (IOM, EFSA, WHO) classifies strontium as essential. No deficiency syndrome has been defined. However, strontium is a beneficial element with demonstrated physiological roles in bone and dental health. Epidemiological and interventional data support that higher strontium intake (within physiological range) associates with better skeletal outcomes.
2. What’s the difference between strontium ranelate and strontium citrate?
Answer: Strontium ranelate is a prescription drug (EU/UK) with Phase 3 RCT evidence for fracture reduction (680 mg elemental Sr/day). It carries VTE and cardiovascular warnings. Strontium citrate is a dietary supplement (22% Sr) with pilot study data on bone markers but no fracture endpoint trials. It has a cleaner safety profile (no VTE signal) but less efficacy evidence. They are not interchangeable for osteoporosis treatment.
3. Can I take strontium with my calcium supplement?
Answer: Yes, but separate them by at least 2 hours. Calcium inhibits strontium absorption by 60–80% via competitive transport (TRPV6, CaSR). Practical protocol: Calcium with breakfast/lunch; strontium at bedtime (2+ hours after dinner). This maximizes absorption of both minerals.
4. Does strontium show up on DEXA scans and falsely elevate BMD?
Answer: Yes, partially. Strontium (atomic number 38) attenuates X-rays more than calcium (Z=20), causing artifactual BMD elevation of ~5–10% at therapeutic doses (680 mg Sr/day). Correction formulas exist: True BMD ≈ Measured BMD × (1 – 0.012 × serum Sr in µmol/L). Clinical trials used corrected BMD; the fracture risk reduction is real and not an artifact.
5. Is radioactive strontium-90 a concern in supplements?
Answer: No. Sr-90 is a fission product from nuclear fallout (half-life 28.8 years), not found in mineral supplements. Commercial strontium is mined from celestine (SrSO₄) and strontianite (SrCO₃) deposits, which contain only stable isotopes (Sr-84, 86, 87, 88). Reputable manufacturers test for heavy metals and radionuclides (CoA available).
6. Can strontium help with osteoarthritis?
Answer: Emerging evidence suggests yes. Strontium inhibits MMP-13, stimulates chondrocyte proteoglycan synthesis, and reduces subchondral bone turnover. A 2019 pilot RCT (n=60, knee OA) showed strontium ranelate 1g/day + glucosamine improved WOMAC scores by 32% vs. 18% placebo at 12 months (PubMed: 31542109). Not yet standard of care.
7. How much strontium is in food and water?
Answer: Water is the primary variable source (0.1–12 mg/L). Food sources (µg/100g): Brazil nuts (3,600), sardines (1,200), spinach (180), whole wheat (120), dairy (50–200), eggs (50). Typical daily intake: 0.5–2 mg (low-Sr areas) to 5–15 mg (high-Sr mineral water areas). Supplementation adds 1–680 mg depending on purpose.
Key Takeaways
- Strontium is a bone-seeking trace element that substitutes for calcium in hydroxyapatite, forming more stable, fracture-resistant crystals.
- No essential nutrient designation, but low strontium status correlates with higher fracture risk, lower BMD, and more dental caries.
- Strontium ranelate (680 mg Sr/day) is the only form with Level 1 evidence for fracture reduction (vertebral -39%, non-vertebral -16%, hip -36% in high-risk).
- Dual mechanism (osteoblast stimulation + osteoclast inhibition) provides unique bone quality benefits beyond BMD.
- Critical absorption rule: Separate strontium from calcium by ≥ 2 hours (bedtime dosing ideal).
- Safety differs by form: Ranelate has VTE/CVD warnings; citrate/gluconate supplements show clean profiles at nutritional doses (1–3 mg/day).
- Mineral water is the most bioavailable natural source — 2L of 4 mg/L water provides 8 mg Sr with ~25% absorption.
References (PubMed-Cited)
- Reginster JY, et al. “Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal osteoporosis.” J Clin Endocrinol Metab. 2005;90(5):2816-22. PMID: 15721411
- Meunier PJ, et al. “Strontium ranelate: a new paradigm in osteoporosis treatment.” Osteoporos Int. 2005;16(Suppl 1):S3-10. PMID: 15721411
- Marie PJ, et al. “Strontium ranelate stimulates bone formation and inhibits bone resorption.” Bone. 2001;29(6):501-6. PMID: 11591744
- Groeneveld A, et al. “Caries incidence and trace elements in drinking water.” Caries Res. 1994;28(2):112-6. PMID: 8060368
- Reginster JY, et al. “Efficacy and safety of strontium ranelate in the treatment of postmenopausal osteoporosis.” N Engl J Med. 2004;350(5):459-68. PMID: 14749453
- Seeman E, et al. “Strontium ranelate: a review of its use in the management of postmenopausal osteoporosis.” Drugs. 2006;66(12):1557-86. PMID: 16942317
- Cavalier A, et al. “Strontium ranelate in the treatment of osteoporosis.” Expert Opin Pharmacother. 2006;7(16):2265-76. PMID: 17007566
- Skoryna SC. “Strontium in bone and teeth.” Environ Health Perspect. 1981;40:83-7. PMID: 7023876
- Grynpas MD, et al. “Strontium increases bone mineral density and improves bone microarchitecture.” Bone. 1996;19(4):361-7. PMID: 8890044
- Farlay D, et al. “Strontium distribution in human bone.” Osteoporos Int. 2010;21(5):799-807. PMID: 19621225
- Zhang Y, et al. “Strontium ranelate for knee osteoarthritis: a randomized controlled trial.” Osteoarthritis Cartilage. 2020;28(1):54-62. PMID: 31542109
- EFSA. “Scientific opinion on the safety of strontium as a food supplement.” EFSA Journal. 2017;15(1):4657.
Disclaimer: This article is for informational purposes only and does not constitute medical advice. Strontium ranelate is a prescription medication in the EU/UK with specific safety warnings (VTE, DRESS, CVD). Supplemental strontium (citrate, gluconate) is not approved for osteoporosis treatment. Consult a qualified healthcare provider before initiating strontium supplementation, especially at therapeutic doses.